药学学报, 2019, 54(3): 540-546
引用本文:
唐开城, 程立婷, 汪小又, 李翀. 一种简便的一氧化碳递送策略及抗脓毒症肺损伤的研究[J]. 药学学报, 2019, 54(3): 540-546.
TANG Kai-cheng, CHENG Li-ting, WANG Xiao-you, LI Chong. A simple strategy for delivery of carbon monoxide against septic lung injury[J]. Acta Pharmaceutica Sinica, 2019, 54(3): 540-546.

一种简便的一氧化碳递送策略及抗脓毒症肺损伤的研究
唐开城, 程立婷, 汪小又, 李翀
西南大学药学院, 重庆 400716
摘要:
一氧化碳(carbon monoxide,CO)是机体内一种重要的化学气体信使分子,具有明确的抗炎活性,但作为一种气态的活性物质,如何安全、有效地递送至病灶发挥疗效有待研究。基于一氧化碳与红细胞(red blood cell,RBC)主要成分血红蛋白的天然亲和性,本文拟构建一种一氧化碳-红细胞(CO-RBC)复合体系,以脓毒症肺损伤为模型,一氧化碳释放分子(carbon monoxide releasing molecule-2,CORM-2)为对照,研究其对模型小鼠肺损伤的治疗作用。以CO-RBC中CO的释放、稳定性、安全性及体内肺靶向性对CO-RBC复合体系进行表征;以细胞间黏附分子(ICAM-1)、肺表面活性蛋白-A(SP-A)的表达评价动物模型;以肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)炎症因子的分泌、小鼠存活时间及肺组织病理变化评价CO-RBC复合体系对脓毒症肺损伤的治疗作用。实验设计获得西南大学实验动物伦理审查委员会批准,符合动物实验福利伦理准则。结果表明:CO-RBC复合体系在氮气保护下储存,稳定性强,48 h内基本无释放,而在近生理条件下时,12 h内释放约70%,解决了CORM-2中CO突释的问题,同时对小鼠无毒性;体内荧光成像显示CO-RBC复合体系能在肺部有效聚集,具有一定的肺靶向作用;给药治疗后,CO-RBC组相较于其他组,TNF-α和IL-6的分泌明显降低,肺间质水肿程度减轻,白细胞浸润减少,存活率显著提高。因此,本研究制备的CO-RBC复合体系相比CORM-2对脓毒症小鼠肺部炎症反应有显著的抑制作用,有望为脓毒症的治疗提供新思路。
关键词:   
A simple strategy for delivery of carbon monoxide against septic lung injury
TANG Kai-cheng, CHENG Li-ting, WANG Xiao-you, LI Chong
College of Pharmaceutical Sciences, Southwest University, Chongqing 400716, China
Abstract:
Carbon monoxide (CO) is an important chemical gas messenger molecule in the body with anti-inflammatory activity. As an active substance in gaseous state, the method for its safe and effective delivery towards the lesion sites remains to be established. Based on the natural affinity of carbon monoxide to hemoglobin, a main component of red blood cells (RBCs), this study proposes a carbon monoxide-red blood cell (CO-RBC) composite system, and tested its therapeutic effect against lung injury in an animal model. The mouse model of septic lung injury was adopted, and the carbon monoxide release molecule (CORM-2) was used as a positive control. CO-RBC system was characterized by CO release, stability, toxicity and in vivo lung targeting. The expression of intercellular adhesion molecule (ICAM-1) and pulmonary surfactant protein-A (SP-A) were evaluated in the animal model and the therapeutic effect of CO-RBC system for sepsis was measured by inflammatory factors tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), as well as survival time of mice and pathological changes of the lung. Our results show that CO-RBC system exhibited satisfactory stability with negligible CO release during 48 h storage under nitrogen protection, while the CO release was about 70% within 12 h under physiological condition, in contrast to CO burst release from CORM-2. The CO-RBC system showed no significant toxicity in the animal model, and in vivo fluorescence imaging results showed effective accumulation in the lungs, supporting its lung targeting effects. The secretion of TNF-α and IL-6 in the CO-RBC group was significantly lower than that in other groups, the degree of pulmonary interstitial edema was relieved, the white blood cell infiltration was decreased, and the survival rate was significantly improved. Therefore, the CO-RBC system has a significant inhibitory effect on the pulmonary inflammatory response in septic mice compared with CORM-2. This system provides a new hope for therapeutic treatment of sepsis.
Key words:   
收稿日期: 2018-12-12
DOI: 10.16438/j.0513-4870.2018-1105
基金项目: 中央高校基本科研业务费专项资金项目资助(XDJK2018AC003).
通讯作者: 李翀
Email: chongli2009@gmail.com
相关功能
PDF(593KB) Free
打印本文
0
作者相关文章

参考文献:
[1] Ortiz-Diaz E, Festic E, Gajic O, et al. Emerging pharmacological therapies for prevention and early treatment of acute lung injury[J]. Semin Respir Crit Care Med, 2013, 34:448-458.
[2] Zhang JX, Sun L, Pang J, et al. Non-targeted metabolomics in septic mice infected with Klebsiella pneumoniae[J]. Acta Pharm Sin (药学学报), 2018, 53:1122-1130.
[3] Kepros JP, Gauvin JM, Reed DN Jr, et al. Acute lung injury:an indicator of serious systemic illness[J]. Curr Surg, 2006, 63:197-201.
[4] Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock[J]. Intens Care Med, 2004, 30:536-555.
[5] Knox DB, Lanspa MJ, Kuttler KG, et al. Phenotypic clusters within sepsis-associated multiple organ dysfunction syndrome[J]. Intens Care Med, 2015, 41:814-822.
[6] Lancel S, Hassoun SM, Favory R, et al. Carbon monoxide rescues mice from lethal sepsis by supporting mitochondrial energetic metabolism and activating mitochondrial biogenesis[J]. J Pharm Experiment Therapeut, 2009, 329:641-648.
[7] Verma A, Hirsch DJ, Glatt CE, et al. Carbon monoxide:a putative neural messenger[J]. Science, 1993, 259:381-384.
[8] Cepinskas G, Katada K, Bihari A, et al. Carbon monoxide liberated from carbon monoxide-releasing molecule CORM-2 attenuates inflammation in the liver of septic mice[J]. Am J Physiol Gastrointest Liver Physiol, 2008, 294:G184-G191.
[9] Jurga AM, Piotrowska A, Starnowska J, et al. Treatment with a carbon monoxide-releasing molecule (CORM-2) inhibits neuropathic pain and enhances opioid effectiveness in rats[J]. Pharmacol Rep, 2016, 68:206-213.
[10] Omer SQ, Zeb A, Akram M, et al. Enhanced acute anti-inflammatory effects of CORM-2-loaded nanoparticles via sustained carbon monoxide delivery[J]. Eur J Pharm Biopharm, 2016, 108:187-195.
[11] Kautz AC, Kunz PC, Janiak C. CO-releasing molecule (CORM) conjugate systems[J]. Dalton Transact, 2016, 45:18045-18063.
[12] Sun B, Sun Z, Jin Q, et al. CO-releasing molecules (CORM-2)-liberated CO attenuates leukocytes infiltration in the renal tissue of thermally injured mice[J]. Int J Biol Sci, 2008, 4:176-183.
[13] Clifton J 2nd, Leikin JB. Methylene blue[J]. Am J Therapeut, 2003, 10:289-291.
[14] Rittirsch D, Huber-Lang MS, Flierl MA, et al. Immunodesign of experimental sepsis by cecal ligation and puncture[J]. Nat Protoc, 2009, 4:31-36.
[15] Li N, Xie H, Li LK, et al. Effects of honokiol on sepsis-induced acute kidney injury in an experimental model of sepsis in rats[J]. Inflammation, 2014, 37:1191-1199.
[16] Dustin ML, Rothlein R, Bhan AK, et al. Induction by IL 1 and interferon-gamma:tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1)[J]. J Immunol, 1986, 137:245-254.
[17] Van Griensven M, Probst C, Müller K, et al. Leukocyte-endothelial interactions via ICAM-1 are detrimental in polymicrobial sepsis[J]. Shock, 2006, 25:254-259.
[18] Hofer S, Bopp C, Hoerner C, et al. Injury of the blood brain barrier and up-regulation of ICAM-1 in polymicrobial sepsis[J]. J Surg Res, 2008, 146:276-281.
[19] Tomasi CD, Vuolo F, Generoso J, et al. Biomarkers of delirium in a low-risk community-acquired pneumonia-induced sepsis[J]. Mol Neurobiol, 2017, 54:722-726.
[20] McCormack FX, Whitsett JA. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung[J]. J Clin Invest, 2002, 109:707-712.
[21] Sano H, Kuroki Y. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity[J]. Mol Immunol, 2005, 42:279-287.
[22] Silveyra P, Floros J. Genetic variant associations of human SP-A and SP-D with acute and chronic lung injury[J]. Front Biosci, 2012, 17:407-429.
[23] Lee MY, Oh YK, Cho JH. Changes of serum tumor necrosis factor-α and interleukin-1β in the sepsis of neonates[J]. J Kor Pediat Soc, 1995, 38:1307-1314.
[24] Zhou XQ, Su C, Li XT, et al. The inhibitory effect of N-p-chlorobenzenesulfonyl-4-aminosalicylic acid on dextran sodium sulfate-induced ulcerative colitis[J]. Acta Pharm Sin (药学学报), 2018, 53:1652-1656.
[25] Lin HC, Lee HS, Chiueh TS, et al. Histopathological assessment of inflammation and expression of inflammatory markers in patients with ketamine-induced cystitis[J]. Mol Med Rep, 2015, 11:2421-2428.
[26] Wu TC,Geng J,Guo WJ,et al.Asiatic acid inhibits lung cancer cell growth in vitro and in vivo by destroying mitochondria[J].Acta Pharm Sin B, 2017, 7:65-72.